Annals of Oncology Advance Access originally published online on June 21, 2006
Annals of Oncology 2006 17(11):1724; doi:10.1093/annonc/mdl130
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
letters to the editor |
Role of platinum-based radio-chemotherapy for locally advanced non-small-cell lung cancer: possible influence of type of platinum on survival data
Department of Respiratory Medicine, Okayama University Hospital, 2-5-1, Shikatacho, Okayama, 700-8558, Japan
*(E-mail: khotta{at}md.okayama-u.ac.jp)
In the March 2006 issue of Annals of Oncology, Dr. Auperin et al. [1] conducted a meta-analysis addressing the role of concomitant platinum-based radio-chemotherapy in locally advanced non-small-cell lung cancer (NSCLC) patients. In this meta-analysis, the authors included both cisplatin- and carboplatin-based regimens within platinum-based chemotherapy. They demonstrated that the concomitant platinum-based radio-chemotherapy yielded a significant absolute benefit of chemotherapy of 4% at 2 years compared with the radiotherapy alone. In spite of indirect comparisons, there was no significant difference between cisplatin- and carboplatin-based chemotherapy in terms of overall survival.
Cisplatin-based chemoradiotherapy has intensively been investigated in patients with locally advanced non-small-cell lung cancer in many randomized trials and is considered to be standard treatment [2]. However, carboplatin-based chemoradiotherapy has not fully been evaluated in terms of overall survival in this population. In addition, no large randomized trials directly comparing these two agents are available. Thus, to date, one cannot affirm the true therapeutic equivalence between cisplatin and carboplatin for locally advanced NSCLC.
Despite our great respect for Dr Auperins' meta-analysis, in these circumstances, we still consider that the role of both cisplatin-based and carboplatin-based radio-chemotherapy should be separately evaluated in the future. We are very pleased to hear that an update of the 1995 meta-analysis on locally advanced NSCLC is now underway [3] and we eagerly await each updated survival result of the agents when combined with thoracic irradiation.
 |
References |
|---|
 Top References |
|---|
1. Auperin A, Le Pechoux C, Pignon JP, et al. (2006) Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 17:473–483.
2. Non-small Cell Lung Cancer Collaborative Group. (1995) Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899–909.
3. Burdett S, Stewart L, Pignon JP. (2005) Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. J Clin Oncol 23:924–925.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||